IMAB
I-Mab
Price:  
0.86 
USD
Volume:  
99,026.00
China | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

IMAB WACC - Weighted Average Cost of Capital

The WACC of I-Mab (IMAB) is 8.6%.

The Cost of Equity of I-Mab (IMAB) is 8.65%.
The Cost of Debt of I-Mab (IMAB) is 7.00%.

Range Selected
Cost of equity 6.30% - 11.00% 8.65%
Tax rate -% - 0.10% 0.05%
Cost of debt 7.00% - 7.00% 7.00%
WACC 6.4% - 10.8% 8.6%
WACC

IMAB WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.54 1.09
Additional risk adjustments 0.0% 0.5%
Cost of equity 6.30% 11.00%
Tax rate -% 0.10%
Debt/Equity ratio 0.06 0.06
Cost of debt 7.00% 7.00%
After-tax WACC 6.4% 10.8%
Selected WACC 8.6%

IMAB's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for IMAB:

cost_of_equity (8.65%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.54) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.